Engineered Bacteria Carry Hidden Phage Payloads to Block Gut Infections in Mice

A new study published in Nature Microbiology reports a strategy that could reshape how lytic bacteriophages are deployed against intestinal pathogens. Rather than delivering phages directly, researchers engineered bacteria to carry prophages—temperate viruses integrated quietly into a bacterial genome—and used these carrier strains as living reservoirs of therapeutic phages. In mouse models of enteric infection, the approach enabled prophylactic phage therapy, releasing lytic phages in the gut precisely when and where they were needed to attack disease-causing bacteria.

The central problem the work addresses is a familiar one in phage therapy: lytic phages are remarkably effective at killing their bacterial targets in a dish, but their performance in the gut often falls short of expectations. The mammalian intestine is a crowded, chemically complex environment in which introduced phages can be diluted by gut transit, inactivated by changes in pH and bile, adsorbed by mucus and particulate matter, or simply outcompeted by the sheer density of resident microbes. Concentrations of phage that would rapidly clear a bacterial culture in vitro may never reach the threshold needed to suppress a pathogen in vivo, particularly when treatment begins before an infection has taken hold.

Prophylactic phage therapy—giving phages in advance of exposure to a pathogen—makes this problem especially acute. If phages are administered orally as free virus particles, they must survive passage through the stomach, persist in the intestinal lumen for an extended period, and remain at effective concentrations until the pathogen arrives. Because lytic phages only replicate when they encounter susceptible host bacteria, a prophylactically delivered phage that meets no target simply decays. The new study’s answer is to stop thinking of the phage as the delivered agent and start thinking of a bacterium as the delivery vehicle.

The researchers engineered bacterial strains to encode prophages in their genomes. A prophage is the integrated, dormant form of a temperate phage: its DNA is replicated along with the host cell’s chromosome and passed to daughter cells at division, effectively turning each carrier bacterium into a self-replicating archive of viral genetic material. Under normal conditions the prophage remains silent, allowing the carrier strain to colonize the gut without being lysed. When the carrier population encounters a susceptible target bacterium—or when conditions trigger prophage induction—the integrated phage can enter its lytic cycle, producing new virions that are then released directly into the intestinal environment.

This design has several consequences that make it attractive as a prophylactic strategy. First, because the phage genome is maintained by a replicating bacterial population, the viral payload is continuously renewed rather than passively decaying, which addresses the persistence problem that undermines conventional prophylactic dosing. Second, phage production occurs in situ, in the same compartment the pathogen will occupy, sidestepping the barriers that degrade or dilute phages delivered from outside. Third, the system couples phage release to the ecology of the gut itself: the carrier strain establishes, persists, and produces virions locally, creating a standing population of lytic phage that is already in position when a pathogen attempts to establish infection.

In the mouse experiments described in the paper, animals that received the prophage-encoding engineered bacteria before pathogen challenge were protected against enteric infection, with the released lytic phages suppressing the target pathogen in the intestine. The authors frame this as prophylactic lytic phage therapy achieved through a biological delivery system—combining the killing power of lytic phages with the persistence and localization of a colonizing bacterial carrier. The results, they argue, demonstrate that engineered prophage carriers can convert the gut itself into a manufacturing site for therapeutic phages.

The technical achievement rests on a set of design decisions that reflect the peculiar biology of temperate phages. A prophage must be stable enough not to spontaneously induce and destroy its own carrier population, yet inducible enough to produce virions on a useful timescale. The carrier strain must be able to colonize the mouse gut without causing harm, must not be eliminated by the resident microbiota, and must not itself become the target of the phage it carries. Immunity mechanisms—typically conferred by prophage-encoded repressors—keep the carrier protected from its own phage, while the phage’s host range determines which pathogens the released virions can attack. Balancing these constraints is the core engineering challenge, and the study’s success in mice suggests the authors found a workable equilibrium.

The work also speaks to a broader conceptual shift in phage therapy. Most clinical and preclinical phage programs treat phages as drugs: purified virus preparations, dosed and formulated like small molecules or antibodies. That paradigm has produced encouraging results in compassionate-use cases and early trials, particularly for antibiotic-resistant infections, but it inherits the pharmacological weaknesses of a self-replicating, target-dependent agent. The prophage-carrier approach instead treats the phage as part of a living system, embedded in a bacterial chassis that handles persistence, localization, and production. In this view, the therapeutic unit is not a vial of virus but an engineered member of the gut community.

That shift brings both opportunities and questions. Living carriers can be designed to respond to environmental cues, to carry multiple prophages against different pathogens, or to be genetically confined through auxotrophy or kill switches—features that are impossible with purified phage preparations. At the same time, releasing engineered organisms and their viral payloads into the gut raises ecological and regulatory questions that purified phages do not: how stably the carrier colonizes, whether the integrated prophage spreads horizontally to other bacteria, how the resident microbiota responds to chronic phage production, and how such a product would be evaluated by regulators accustomed to defined molecular drugs. The mouse data establish proof of principle; translating it will require answering these questions in more complex microbial communities and, eventually, in hosts whose guts differ substantially from those of laboratory mice.

The study also contributes to a growing literature on the natural role of prophages in gut ecology. Most bacteria in the mammalian intestine carry prophages, and induction of these elements under stress conditions is increasingly recognized as a driver of bacterial competition and microbiome dynamics. The engineered system described in Nature Microbiology essentially harnesses a natural phenomenon—prophage carriage and induction—for a therapeutic purpose, turning a widespread biological mechanism into a controllable intervention. Whether that intervention can be made safe, predictable, and generalizable remains to be seen, but the mouse results mark a concrete step toward phage therapies that are deployed not as doses but as residents.

For a field confronting the relentless spread of antibiotic resistance in enteric pathogens, the appeal of a prophylactic strategy is obvious. Preventing an intestinal infection before it establishes is easier, safer, and cheaper than treating one that has already taken hold, and phages offer a specificity that broad-spectrum antibiotics cannot match—killing the pathogen while sparing the rest of the community. By encoding that specificity in a colonizing bacterium, the new work proposes a way to keep the weapon loaded and in place until it is needed. If the approach survives the translational challenges ahead, prophage-encoding carriers could become a template for a new class of living, prophylactic antimicrobials designed to guard the gut against its most dangerous inhabitants.

Subject of Research: Engineering prophage-encoding bacteria as living carriers for prophylactic lytic phage therapy against enteric infection in mice

Article Title: Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice

Article References: Bataglioli, R. A., Baaziz, H., Avalos, H. F., Smith, L., Baker, Z. R., Makhlouf, R. J., da Silva Barreira, D., Kaur, H., Southard, T., & Hsu, B. B. (2026). Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02484-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02484-3

Keywords: bacteriophage therapy, prophage, engineered bacteria, enteric infection, gut microbiome, lytic phage, prophylaxis, mouse model, antimicrobial resistance, synthetic biology, Nature Microbiology, phage delivery